The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.
Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella...
Xavier Salvatella, ICREA researcher at IRB Barcelona, proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.
The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.
The Catalan Media Corporation, La Razón and Aldia.cat have highlighted a study conducted by Xavier Salvatella, ICREA researcher at IRB Barcelona, and published in the journal Structure early in December. In this work, he proposes various ways to tackle prostate cancer and focuses on the androgen receptor protein, which tumour cells need to survive and proliferate.
Link to CCMA
A study at IRB Barcelona sheds light on the dynamics of protein aggregates that behave like “droplets of oil in water” and that are described as membraneless cytoplasmic organelles.
These organelles regulate protein activity during cell division.
This is the first study at the Institute to address the so-called liquid-like droplets, which are attracting the attention of researchers worldwide.
El Heraldo de Aragon and other media have echoed the research headed by Xavier Salvatella, group leader of the Laboratory of Molecular Biophysics at IRB Barcelona. The study, published in ACS Chemical Biology found—contrary to what was believed until now—that disordered regions of proteins can be used as therapeutic targets and that they may have applications on Alzheimer's, Parkinson's and prostate cancer.
The finding paves the way for the identification of new therapeutic targets for many diseases.
Kennedy’s disease leads to progressive muscle wastage. It is a condition that affects only men and it appears between 40 and 50 years of age. There is no specific treatment available.
In individuals with this disease, muscle cells and motor neurons die over the years because they accumulate a protein that is mutated.
Researchers at IRB Barcelona discover that this protein has a self-protective mechanism through which the deleterious effects of the mutation are delayed.
The European Research Council (ERC) has written an ERC Story about Xavier Salvatella, ICREA researcher and leader of the Laboratory of Mollecular Biophysics.
Professor Salvatella is an ERC grantee, whose research is focused in looking for new prostatic cancer therapies that would bypass the resistance that some pacients develop over time. In particular, he studies the folding of the protein androgen...
The European Research Council (ERC) has devoted an ERC story to Xavier Salvatella, ICREA researcher and head of the Laboratory of Molecular Biophysics. Salvatella holds an ERC Consolidator Grant to study how the protein androgen receptor folds and how mutations in this protein are linked to drug resistance developed in late-stage prostate cancer patients. This research may open the door to new therapies....
The second video, "Magical Choreography" (02:52), is devoted to Xavier Salvatella, ICREA researcher and holder of an ERC grant, awarded in 2015.
This biophysicist studies protein folding using the Androgen receptor as a model—a receptor linked to Kennedy disease —a rare neurodegenerative condition —and also to prostate cancer.
His research could lead to new drug treatments for both conditions. "Doing what we do is an honour but also a responsibility," says the scientist.